Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Cognitive impairment predates psychosis onset

People at clinical or familial risk for schizophrenia have similar cognitive deficits to those in patients with first-episode schizophrenia, a study shows.

26 Nov 2013

Environment plays primary role in psychosis transition

Research suggests that exposure to environmental risk factors may be necessary for individuals at genetically high risk for psychosis to transition from good health to the psychiatric disorder.

22 Nov 2013

Childhood trauma link to bipolar symptoms strengthened

Research confirms a link between childhood trauma and severe symptoms of bipolar disorder in adults.

22 Nov 2013

Novel drug combats psychosis in Parkinson’s disease

The non-dopaminergic drug pimavanserin reduces psychotic symptoms in patients with Parkinson’s disease without worsening motor function, shows a randomized trial.

22 Nov 2013

Treatment key to averting psychosis violence after prison release

The risk for violence after the release of prisoners with sexual or violent offences is increased if they have untreated psychosis, a study shows.

21 Nov 2013

Released prisoners with schizophrenia three times more likely to be violent than other prisoners

New research from Queen Mary University of London shows released prisoners with schizophrenia are three times more likely to be violent than other prisoners, but only if they receive no treatment or follow-up support from mental health services.

21 Nov 2013

Stroke may be associated with smoking synthetic marijuana

Add stroke to the list of severe health hazards that may be associated with smoking synthetic marijuana, popularly known as spice or K2, a University of South Florida neurology team reports.

20 Nov 2013

Cerebral basis for positive psychosis symptoms pinpointed

Altered activation in the secondary somatosensory cortex during sensorimotor experiences may underlie the flawed judgments resulting in positive schizophrenia symptoms, research suggests.

19 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Gray matter changes reflect psychosis burden

Changes in gray matter volume may be associated with psychosis burden rather than clinical diagnosis, research suggests.

14 Nov 2013

Mood disorder subtypes remain in the family

Psychosis, mania, and depression are unlikely to have shared hereditary causes, report researchers in Molecular Psychiatry.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Population genetic studies may have limited role in schizophrenia

Studying the genetics of people in the general population who have psychotic experiences is unlikely to yield useful information about schizophrenia, say researchers.

6 Nov 2013

Lack of neurocognitive gender differences in early psychosis

Impairments in neurocognition do not occur at a higher rate in males than in females at the onset of psychosis, suggest findings published in Progress in Neuro-Psychopharmacology and Biological Psychiatry.

5 Nov 2013

First-episode type predicts morbidity, disease course in bipolar disorder

Study findings suggest that the type of first episode in patients with bipolar disorder can predict the type and degree of future morbidity, as well as the disease course.

5 Nov 2013

Metacognitive training complements antipsychotic therapy

Metacognitive training may benefit patients with schizophrenia who only partially respond to antipsychotic treatment, study findings show.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013